Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease-Reference-Cited by-同舟云学术

Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease

Published:2023-07 Issue:1 Volume:164 Page:53-64
ISSN:0012-3692
Container-title:CHEST
language:en
Short-container-title:CHEST

Author:

Henkle Emily^ORCID,Quittner Alexandra L.,Dieckmann Nathan F.,Franklin Heather^ORCID,Brunton Amanda E.^ORCID,Daley Charles L.^ORCID,Winthrop Kevin L.,Strnad Luke,Varley Cara,Lapidus Jodi,Philley Julie,McShane Pamela,Devine Megan,Griffith David E.,Kasperbauer Shannon H.,Huitt Gwen,Eddy Jared J.,Marras Theodore K.,Brode Sarah K.,Addrizzo-Harris Dorreen,Springer Amy,Flume Patrick,Mingora Christina,Alkabab Yursa,Dorman Susan,Naureckas Ted,Aksamit Timothy R.,Ruoss Stephen,Hornick Douglas B.,Mirsaeidi Mehdi,Salathe Matthias,Waller Stephen,Schmid Andreas,ElMaraachli Wael,Cowell Anne,Thakur Neeta,Nahid Payam,Zha Shoshana,Ignatius Elisa H.,Zenilman Jonathan,Cohen Keira,Belz Daniel C.,Ali Juzar,Lapinel Nicole,Swenson Colin,Kapolka Rebecca,Horne David,Salerno Daniel,DiMango Angela,Moretta Dafne,Tan Laren,Furukawa Brian,Wysham Nicholas,Noone Peader,Daniels Leigh Anne,Chris Saddler ,Misch Elizabeth Ann,Hayes Lisa,Epstein Marcia,Kim Angela,Myers Janet N.

Funder

National Heart, Lung, and Blood Institute

AstraZeneca

Patient-Centered Outcomes Research Institute

National Center for Advancing Translational Sciences

National Institutes of Health

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference24 articles.

1. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline;Daley;Clin Infect Dis,2020

2. US Food and Drug Administration, Center for Drug Evaluation and Research. Draft guidance for industry: nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex: developing drugs for treatment. 2021. Accessed March 3, 2023. https://www.fda.gov/media/152501/download

3. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases;Griffith;Am J Respir Crit Care Med,2007

4. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype;Koh;Eur Respir J,2017

5. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis;Quittner;Chest,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of health-related quality of life in patients with nontuberculous mycobacterial pulmonary disease: A comprehensive review;Respiratory Investigation;2024-11

2. Current challenges in pulmonary nontuberculous mycobacterial infection: a case series with literature review;Postgraduate Medicine;2024-09-12

3. Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease;Antimicrobial Agents and Chemotherapy;2024-05-17

4. Improvement in Health-Related Quality of Life Following Antibiotic Treatment in Nontuberculous Mycobacterial Pulmonary Disease: Initial Analysis of the NTM-KOREA Cohort;Clinical Infectious Diseases;2024-04-02

5. Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease;Nature Reviews Drug Discovery;2024-02-28